Lumicell Revenue and Competitors
Estimated Revenue & Valuation
- Lumicell's estimated annual revenue is currently $13.8M per year.
- Lumicell received $28.7M in venture funding in December 2017.
- Lumicell's estimated revenue per employee is $251,000
- Lumicell's total funding is $33M.
Employee Data
- Lumicell has 55 Employees.
- Lumicell grew their employee count by 12% last year.
Lumicell Competitors & Alternatives
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5M | 20 | N/A | N/A | N/A |
#2 | $5.5M | 22 | -8% | N/A | N/A |
#3 | $5630M | 6705 | 6% | $450M | N/A |
#4 | $5M | 20 | N/A | N/A | N/A |
#5 | $9.3M | 37 | N/A | N/A | N/A |
#6 | $3.8M | 15 | N/A | $44M | N/A |
#7 | $50.2M | 200 | -5% | N/A | N/A |
#8 | $21.8M | 87 | -2% | N/A | N/A |
#9 | $18.6M | 74 | -21% | N/A | N/A |
#10 | $4M | 16 | -6% | N/A | N/A |
What Is Lumicell?
Lumicell is a leader in the field of image-guided cancer surgery. Lumicell technology illuminates cancer cells in the tumor cavity, enabling physicians to take action in real time to improve patient outcomes. The company's lead product, consisting of a fluorescent optical contrast agent and a handheld illumination device, is currently under clinical investigation in patients undergoing breast cancer surgery. A planned pivotal study aims to evaluate the ability of the technology to reduce positive margin rates and reduce repeat surgeries while sparing healthy tissue. Lumicell technology is also being investigated in colorectal cancer, Barrett's Esophagus, pancreatic cancer, and brain metastases. In clinical studies to date, no cancer has been missed and the safety profile of the optical contrast agent has been demonstrated.
keywords:Biotechnology,Healthcare,Medical Devices,Medical Diagnostics,Pharmaceuticals
$33M
Total Funding
55
Number of Employees
$13.8M
Revenue (est)
12%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Lumicell News
If successful, the device can prevent repeat operations, potentially saving the healthcare system nearly $1 billion annually, according to a statement from Lumicell. The cash infusion will fund the 400-person pivotal trial of the Lumicell Margin Assessment System, to be conducted at several hea ...
Lumicell, Inc., a Wellesley, Mass.-based technology leader in the field of image-guided cancer surgery, raised $28.7M in Series C financing. Backers included Launch Capital and BlueIO. The company intends to use the funds to continue to develop its LUM system pipeline including plans to initia ...
Leverages Broad Potential of LUM System with Drug, Device and Software for Real-time Detection of Tumor Tissue in Patients During Surgery WELLESLEY, Mass.--(BUSINESS WIRE)--Lumicell, Inc., a technology leader in the field of image-guided cancer surgery, today provided an update on the company’s ...
Lumicell said it completed enrollment in a Phase C feasibility clinical trial for its intraoperative breast cancer imaging system. The Newton, Mass ...
Innoblative Designs last week named former Lumicell chief executive Kelly Londy as its new CEO. Apart from her two-year stint at the Lumicell ...
Lumicell- Experts are testing a new innovative imaging technology at Massachusetts General Hospital. The imaging technology can enhance ...
Other Companies in Wellesley
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $6.6M | 61 | 15% | N/A |
#2 | $14.9M | 66 | 69% | N/A |
#3 | $9.8M | 68 | 13% | N/A |
#4 | $14.3M | 70 | 32% | N/A |
#5 | $16.5M | 75 | -9% | N/A |
Lumicell Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2014-01-07 | $1.0M | B | Article | |
| 2016-05-09 | $6.8M | Undisclosed | Article | |
| 2017-07-13 | $Undisclosed | Undisclosed | Article | |
| 2017-10-25 | $20.7M | Undisclosed | Article | |
| 2017-12-08 | $28.7M | C | Launch Capital | Article |
